Research and Clinical Trials

Innovative Clinical Research

The Barnabas Health Heart Centers participate in more clinical research trials than any other cardiac program in New Jersey. Our prominent cardiovascular research helps patients gain access to promising new treatments and technology.

The cardiovascular research team participates in industry sponsored and investigator initiated research projects in a variety of subspecialties including diagnostic, invasive and non-invasive cardiology; electrophysiology; heart failure management; as well as cardiothoracic surgery and cardiac transplant.

The team works closely to incorporate research findings into the comprehensive care to improve patient outcomes.

For more information about research trials at the Barnabas Health Heart Centers, please contact the Cardiac Research Team at 973-926-8451.

CURRENT TRIALS

HW-004 DT - HeartWare, Inc. - A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System (VAS) for Destination Therapy of Advanced Heart Failure
Principal Investigator: Mark Zucker, MD, JD

Ixmyelocel-T and Dilated Cardiomyopathy (STEM Cell) - Aastrom - A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of transendocardial injection of ixmyelocel-T in subjects with heart failure due to ischemic dilated cardiomyopathy [PROTOCOL NUMBER: 55-1202-1]
Principal Investigator: Mark Zucker, MD, JD

Tafamidis Meglumine (PF-06291826) Protocol # B3461028 - Pfizer, Inc. - A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)
Principal Investigator: Mark Zucker, MD, JD

ALN-TTRSC-004 - Alnylam Pharmaceuticals, Inc. - A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Principal Investigator: Mark Zucker, MD, JD

HeartMate 3/ Momentum 3 -Thoratec Corporation - "Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3™"
Principal Investigator: Margarita Camacho, MD

DREAM HF-1 - Teva Branded Pharmaceutical Products R&D, Inc. - A Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either(rexlemestrocel-L) in Patients Ischemic or Nonischemic Etiology: DREAM HF-1
Principal Investigator: Janice Pieretti, MD

The OneTAC - David Baran, MD - Once-a-day Tacrolimus Conversion Study: The OneTAC Trial
Principal Investigator: David Baran, MD

The PARTNER II Trial with Registries - Edwards Lifesciences, LLC -The Safety and Effectiveness of the SAPIEN XT™ Transcatheter Heart Valve with NovaFlex and Ascendra delivery systems in Intermediate and High Risk for Aortic Valve Surgery and Patients Who Cannot Undergo Surgery
Principal Investigator: Mark Russo, MD, MS

PARTNER 3 - Edwards Lifesciences, LLC - A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Requiring Aortic Valve Replacement who have Severe, Calcific, Symptomatic Aortic Stenosis
Principal Investigator: Mark Russo, MD, MS

PORTICO -St. Jude Medical, Cardiology Division, Inc. - PorticoTM Re-sheathable Transcatheter Aortic Valve System US IDE Trial
Principal Investigator: Mark Russo, MD, MS

PIONEER AF-PCI - Janssen Scientific Affairs, LLC - An open label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention.
Principal Investigator: Marc Cohen, MD

[ top ]